The human embryonic stem cell line RCe007-A (RC-3) was derived from a blastocyst voluntarily donated as unsuitable and surplus to fertility requirements following ethics committee approved informed consent under licence from the UK Human Fertilisation and Embryology Authority. The cell line shows normal pluripotency marker expression and differentiation to the three germ layers in vitro. It has a normal 46XX female karyotype and HLA and blood group typing data is available. 
Resource table Resource details
RCe007-A (RC-3) was derived from a fresh blastocyst that was surplus to requirement or unsuitable for clinical use. The cell line was derived by whole embryo outgrowth on mitotically inactivated human fibroblast (HDF) feeder cells using HDF conditioned medium and expanded under feeder free conditions. RCe007-A (RC-3) was shown to be pluripotent by expression of Oct-4, Nanog, Sox-2, Tra-1-60 and Tra-1-81, but not SSEA-1, using immunocytochemistry (Table 1, Fig. 1 ). By flow cytometric analysis, the expression of pluripotency makers Oct-4 and SSEA-4 was 86.2% and 96.8%, respectively, whereas low expression of the differentiation marker SSEA-1 (5.9%) was observed (Fig. 2) . Differentiation to the three germ layers, endoderm, ectoderm and mesoderm, was demonstrated using embryoid body formation and expression of the germ layer markers α-fetoprotein, β-tubulin and muscle actin (Fig. 3) .
HLA Class I and II typing is available and blood group genotyping gave the blood group O 1 O 1 (Table 2 ).
Verification and authentication
The cell line was analysed for genome stability by G-banding (Fig. 4) and showed a normal 46XX female genotype. The cell line is free from mycoplasma contamination as determined by RT-qPCR.
Materials and methods

Ethics
Derivation of hESC from surplus to requirement and failed to fertilise/develop embryos was approved by The Scotland A Research Stem Cell Research 16 (2016) 
Contents lists available at ScienceDirect
Stem Cell Research j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / s c r Ethics Committee and local ethics board at participating fertility clinics and conducted under licence no R0136 from the UK HFEA with informed donor consent.
Cell culture
Fresh embryos were cultured EmbryoAssist (Origio (Medicult), Denmark) until Day 3 or BlastAssist (Origio) after Day 3 of development. Embryos were cultured at 36.5-37.5°C, 5.0 ± 0.5% CO 2 , 5.0 ± 0.5% O 2 in drops under paraffin oil (Origio) and transferred to fresh medium at least every 2-3 days.
By Day 8 of development, or when spontaneous hatching occurred, embryos were placed in derivation conditions consisting of mitotically inactivated neonatal human dermal fibroblasts (HDFs) (ThermoFisher Scientific (Cascade Biologics), Paisley, UK) on tissue culture plastic precoated with 2 μg/cm 2 human laminin (Sigma Aldrich, Dorset, UK)
as per manufacturer's recommendation. If required, assisted hatching was performed by removing the zona pellucidae mechanically using Swemed cutting tools (Vitrolife, Göteborg, Sweden).
HDF cells were cultured in DMEM (Lonza, Slough, UK), 10% FCS (GE Healthcare (PAA), Buckinghamshire, UK) and 2 mM L-glutamine (ThermoFisher Scientific). HDF were mitotically inactivated using gamma irradiation at 50 Gy using a Gammacell Elite 1000 machine. For use as a feeder layer, irradiated HDFs were plated at 2-50,000 cells/cm 2 in HDF conditioned medium (80% Knockout-DMEM, 20%
Knockout serum replacement (KOSR), 1 mM glutamine, 0.1 mM β-mercaptoethanol, 1% nonessential amino acids, and 4 ng/ml human bFGF (all ThermoFisher Scientific) over 24 h intervals over 7 days) supplemented with an additional 24 ng/ml human bFGF Cells were cultured at 36.5-37.5°C, 5.0 ± 0.5% CO 2 , 5.0 ± 0.5% O 2 and 50% medium exchanged 6 days a week. The established cell line was expanded and banked using CellStart matrix and Stempro hESC Serum Free Medium (ThermoFisher Scientific). Passaging was performed mechanically using an EZ passage tool (ThermoFisher Scientific). hESC lines were expanded to 25-30 wells of a 6-well plate and cryopreserved in 0.5-1 ml KOSR based cryopreservation solution (75% KO-DMEM, 15% Xeno-free KOSR (ThermoFisher Scientific) and 10% DMSO (Origen Biomedical, Texas, USA)) or Cryostor CS10 (Biolife Solution, Washington, USA). To show differentiation to three germ layers Expression of muscle actin, β-tubulin and α-feto protein Fig. 1 . RCe007-A (RC-3) expresses pluripotency markers Oct-4, Nanog, Sox-2, Tra-1-60 and Tra-1-81, but not SSEA-1. Cell nuclei are counterstained with DAPI (blue).
Mycoplasma
Mycoplasma detection was performed using Applied Biosystems PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit and MicroSEQ™ Mycoplasma Real-Time PCR Detection Kit (ThermoFisher Scientific (Applied Biosystems)) according to the manufacturer's instruction.
Endotoxin
Endotoxin levels were determined using the Kinetic-QCL assay (Lonza) and an incubating plate reader (BioTek ELx808) according to the manufacturer's instructions. Briefly, an unknown sample was compared with a standard curve of known levels of control endotoxin. An assay was deemed valid if the coefficient of correlation, r ≥ 0.980 and the CV (%) for the standard curve was ≤10%.
Flow cytometry
Pluripotency was determined using the Human and Mouse Pluripotent Stem Cell Analysis kit (BD, Oxford, UK). Oct-3/4 and SSEA-4 were included as pluripotency markers, and SSEA-1 as a differentiation marker. Fixed and permeabilised cells were analysed using a FACS Aria flow cytometer (BD).
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde (ThermoFisher Scientific (Alfa Aesar)), permeabilised using 100% ethanol (ThermoFisher Scientific) and stained with AFP (1:500; Sigma), β-tubulin III (1:1000; Sigma), muscle-specific actin (1:50; DAKO, Glostrup, Denmark), Oct-4 (1:200; Santa Cruz Biotechnlogy, Texas, USA), Nanog (1:20; R&D Systems, Abingdon, UK), Sox-2, Tra-1-60, Tra-1-81, SSEA-1 (all 1:50; BD) Fig. 2 . RCe007-A (RC-3) was subjected to flow cytometry analysis for markers of pluripotency with specific antibody or isotype control as indicated above the histograms. Percentage staining is indicated in Table 1 . Fig. 3 . In vitro differentiation of RCe007-A (RC-3) to ectoderm (β-tubulin III), mesoderm (muscle actin), and endoderm (α-fetoprotein). Specific staining shown in green, cell nuclei are counterstained with DAPI (blue).
Table 2
Blood group and HLA tissue typing results for RCe007-A (RC-3).
and secondary antibodies anti-mouse IgG-FITC (1:200; Sigma), anti mouse IgG-AlexaFluor 488, anti-goat IgG-AlexaFluor 488, anti-goat IgG-AlexaFluor-594 and donkey polyclonal AlexaFluor-594) (all 1:200; ThermoFisher Scientific). Images were acquired using a Zeiss S100 Axiovert fluorescence microscope or Nikon eC1 confocal microscope.
In vitro differentiation
hESCs were pre-treated for 1 h with 10 μM ROCK inhibitor in Stempro hESC SFM (ThermoFisher Scientific) and embryoid bodies EBs generated in ultra low attachment plates (Corning) for 7 days before being transferred into EB medium (20% FBS (GE Healthcare (PAA)), 80% KO-DMEM 1 mM L-glutamine, 0.1 mM β-mercaptoethanol, 1% nonessential amino acids (all ThermoFisher Scientific)), on glass slide tissue culture chambers (Nunc, ThermoFisher Scientific) coated with 0.5% gelatin (Sigma) at 0.1 ml/cm 2 for 14 days.
Genomic analysis
All outsourced assays were carried out under a Quality and Technical Agreement. DNA was extracted using the QIAamp DNA Mini kit (Qiagen, Manchester, UK) according to manufacturer's recommendations and provided in recommended quantities to the service providers.
Human Leukocyte Antigen (HLA) tissue typing was carried out by the Scottish National Blood Transfusion Service.
Blood group genotyping was carried out by the Molecular Diagnostics laboratory at NHSBT.
Karyotype analysis was carried out by The Doctors Laboratory (London, UK) or the Western General Cytogenetics Laboratory (Edinburgh, UK) Live cells at 60-70% confluency were shipped overnight in warm containers, fixed and analysed by standard G-banding analysis. For research grade lines, 20 spreads were analysed.
